[Efficacy and safety of ibuprofen for the treatment of patent ductus arteriosus in preterm infants of different postnatal ages]
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early ibuprofen treatment for hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants leads to higher closure rates. This approach is safe and does not increase adverse events in neonates.
Area Of Science
- Neonatology
- Pediatric Cardiology
- Pharmacology
Background
- Hemodynamically significant patent ductus arteriosus (hsPDA) is a common complication in preterm infants.
- Pharmacological treatment with ibuprofen is a standard therapy for hsPDA.
Purpose Of The Study
- To assess the efficacy and safety of ibuprofen for hsPDA treatment in preterm infants.
- To investigate the impact of postnatal age at treatment initiation on outcomes.
Main Methods
- Retrospective review of 100 preterm infants (<37 weeks gestation) treated with ibuprofen for hsPDA.
- Infants were categorized into three groups based on postnatal age at ibuprofen initiation: ≤4 days, 5-7 days, and >7 days.
- Comparison of clinical efficacy and safety indicators across the groups.
Main Results
- Higher ductal closure rates were observed with earlier ibuprofen administration (92% in ≤4 days group vs. 72% in 5-7 days and 60% in >7 days group).
- Effective rates showed a similar trend, with earlier treatment being more effective.
- No significant differences in adverse events (pulmonary hemorrhage, GI bleeding, cholestasis, BPD, NEC, ICH, AKI) were found among the groups.
Conclusions
- Earlier administration of oral ibuprofen for hsPDA in preterm infants significantly improves ductal closure rates.
- Initiating ibuprofen treatment within the first week of life does not elevate the risk of adverse events.
- Timing of ibuprofen therapy is a critical factor in optimizing hsPDA treatment outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...